Literature DB >> 21355014

Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins.

Jenna Waldron1, Craig Webster.   

Abstract

BACKGROUND: Mevalonic acid (MVA) is synthesized at an early and rate-limiting step in the biosynthesis of cholesterol by the enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, and is a useful measure of statin efficacy or treatment. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the measurement of serum MVA has been developed.
METHODS: Following the in vitro conversion of MVA to mevalonic acid lactone (MVAL) in the serum, MVAL and a deuterated internal standard were extracted using an online solid-phase extraction procedure. Chromatographic separation was achieved using a Luna PFP column (Phenomenex), with enhanced selectivity and improved resolution for polar compounds. A gradient system was used, with mobile phase comprising methanol and water (5 mmol/L ammonium formate buffer, pH 2.5). Analysis was performed using an API 5000 tandem mass spectrometer (Applied Biosystems) in positive electrospray ionization mode.
RESULTS: The method showed excellent recoveries (98 ± 8%) and imprecision (intra-assay coefficient of variation of 2.2% [6.5 ng/mL] and 2.6% [10.5 ng/mL], and inter-assay coefficient of variation of 9% [10.5 ng/mL]). The assay provides a calibration range up to 50 ng/mL with a limit of detection at 0.1 ng/mL.
CONCLUSION: A simple, rapid and analytically specific method has been developed for the measurement of serum MVA, in the form of MVAL. The high analytical sensitivity of the method allows for accurate quantitation of MVAL in serum samples, both at the endogenous levels found in healthy individuals and in statin-treated patients where normal levels are expected to be greatly reduced through the inhibition of HMG-CoA reductase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355014     DOI: 10.1258/acb.2010.010182

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  4 in total

1.  Analysis of the Impact of Rosuvastatin on Bacterial Mevalonate Production Using a UPLC-Mass Spectrometry Approach.

Authors:  J A Nolan; M Kinsella; C Hill; S A Joyce; C G M Gahan
Journal:  Curr Microbiol       Date:  2016-03-10       Impact factor: 2.188

2.  An ultrasensitive enzymatic method for measuring mevalonic acid in serum.

Authors:  Takeshi Matsuoka; Shigeru Ueda; Hideyuki Matsumoto; Masanobu Kawakami
Journal:  J Lipid Res       Date:  2012-06-19       Impact factor: 5.922

3.  Optimization, validation and application of an assay for the activity of HMG-CoA reductase in vitro by LC-MS/MS.

Authors:  Jing Wang; Ji-Ye Sun; Chun-Jie Sha; Yu-Feng Shao; Yan-Hong Liu; You-Xin Li; Zhen-Wen Duan; Wan-Hui Liu
Journal:  J Pharm Anal       Date:  2015-07-03

4.  Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate.

Authors:  Chloë Goossens; Ruben Weckx; Greet Van den Berghe; Lies Langouche; Sarah Derde; Sarah Vander Perre; Inge Derese; Paul P Van Veldhoven; Bart Ghesquière
Journal:  Crit Care       Date:  2021-07-17       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.